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The intimate relationship between
embryogenesis and oncogenesis has
long been a prevailing theme in cancer
biology. This theme is well exemplified by
the homeobox gene family, whose vari-
ous members mediate a plethora of
embryonic functions, while their deregu-
lation may be associated with tumorigen-
esis. Nonetheless, despite the many
instances in which aberrant homeobox
gene expression has been found to
occur in solid tumors, until recently there
have been relatively few cases in which
such misexpression has been definitively
associated with carcinogenesis (Abate-
Shen, 2002). The study by Gidekel et al.
(2003) provides an elegant example,
showing that a homeobox gene that is
normally required for differentiation of a
particular tissue can play a causal role in
carcinogenesis of that same tissue if
expressed at the wrong time, at the
wrong levels, or in the wrong contexts. In
particular, the authors demonstrate that
Oct-4 (also known as Oct-3 and POU5f1),
which is normally expressed in germ
cells and is required for their maintaining
their pluripotency (Nichols et al., 1998;
Niwa et al., 2000), can promote tumori-
genesis when expressed inappropriately
in these same cells.
In normal circumstances, Oct-4 is
restricted to pluripotent cells of the early
embryo and those of the germ cell lin-
eage, while its downregulation is associ-
ated with loss of pluripotentiality of these
cells (Nichols et al., 1998; Niwa et al.,
2000). The study by Gidekel et al., as
well as work of Looijenga and colleagues
(Looijenga et al., 2003), show that Oct-4
is expressed in each of the various types
of testicular germ cell tumors, which
comprise a heterogeneous group of neo-
plasia, including embryonal carcinomas,
seminomas, and mixed germ cell tumors,
as well as their common precursor,
intratubular germ cell neoplasia. Although
Oct-4 expression is observed in most, if
not all, testicular germ cell tumors, it is
not found in other solid tumors (Gidekel
et al., 2003; Looijenga et al., 2003).
During development, Oct-4 expres-
sion is required to maintain the pluripo-
tency of the inner cell mass (ICM) cells,
which give rise to all fetal cell types; in
the absence of Oct-4, ICM cells differen-
tiate into trophoectoderm, which gives
rise to extraembryonic tissue (Nichols et
al., 1998; Niwa et al., 2000). Using a
cleverly engineered series of embryonal
stem (ES) cells in which the levels of
Oct-4 expression can be controlled from
0% to 150% of wild-type by varying the
number of Oct-4 alleles and by using an
inducible exogenous transgene (Niwa et
al., 2000), Austin Smith and colleagues
showed that the amount of Oct-4 can
determine cell fate (Figure 1). Thus, the
lowest levels of Oct-4 expression lead to
trophoectoderm differentiation, interme-
diate levels are associated with the
pluripotent stem cells, and the highest
levels promote differentiation of primitive
endoderm (Niwa et al., 2000).
These same ES cells have now been
used to demonstrate that the dosage of
Oct-4 protein is directly related to the
tumorigenic potential of these cells
(Figure 1). In particular, Gidekel et al. find
that as Oct-4 expression is increased
from 0% to 150% of wild-type, the poten-
tial for these ES cells to form tumors in
syngeneic hosts shifts from about 4% at
the lowest level of Oct-4 expression to
better than 80% at the highest levels and
is associated with an increased accumu-
lation of malignant versus nonmalignant
cells (Gidekel et al., 2003).
Not only is tumor incidence coinci-
dent with the levels of Oct-4 expression,
their sustained growth is dependent on
its continued expression since the tumors
regressed upon lowering Oct-4 expres-
sion (i.e., by turning off the inducible
exogenous gene). This is analogous to
the tumor dependence of other onco-
genes such as RAS, for example, in
which its removal by turning off the
inducible gene also leads to tumor
regression (Chin, 2003), whereas elimi-
nation of other oncogenes, such as Myc,
does not lead to tumor regression 
under all circumstances (Pelengaris et
al., 2002).
The implication of these findings is
that some, but not all, tumors may
require a single oncogene for mainte-
nance of the transformed state. If these
observations are confirmed to be rele-
vant for the growth of testicular germ cell
tumors in humans, Oct-4 would repre-
sent an attractive target for therapeutic
intervention. Importantly, because the
level of Oct-4 expression is critical for
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Figure 1. Diagram showing the relationship of
Oct-4 expression levels to the occurrence 
of normal and cancer cell types
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tumorigenesis, it would only be neces-
sary to lower its expression to achieve
the desired outcome, which is of course
more feasible than eliminating it totally.
In a broader context, the study by
Gidekel et al., as well as previous studies
in the literature (Abate-Shen, 2002),
contribute to our understanding of how
homeobox genes may be functionally
relevant for oncogenesis, as well as how
they may differ from other classes of can-
cer-promoting genes. First of all, deregu-
lated expression of homeobox genes in
solid tumors typically displays tissue
specificity; although Oct-4 is expressed
in virtually all germ cell tumors, it is not
expressed in other solid tumors. In this
regard, homeobox genes provide attrac-
tive candidates for modulating the tissue-
specific features of cancer phenotypes,
presumably acting in conjunction with
broad-spectrum oncogenes or tumor
suppressors.
Secondly, deregulation of homeobox
genes may occur early in carcinogene-
sis; expression of Oct-4 was prevalent in
precursor lesions of germ cell tumors as
well as in the tumors themselves. This
parallels the situation with other hom-
eobox genes, including Nkx3.1 and
Cdx2, which are also downregulated at 
the earliest stages of carcinogenesis of 
the prostate and colon, respectively.
Considering that homeobox genes are
likely to regulate the differentiation status
of tissues in which they are expressed,
one can speculate that their deregulated
expression perturbs the normal differen-
tiation program, thereby predisposing to
neoplasia.
Thirdly, homeobox genes are un-
usual in the sense that their deregulation
can be manifest either as an up- or
downregulation of expression, depend-
ing upon the particular gene and the
timing of its expression in normal scenar-
ios (Abate-Shen, 2002). Thus, Oct-4 falls
into the category of homeobox genes
whose expression during development is
restricted to undifferentiated precursors
of developing tissues, while its expres-
sion is reactivated in neoplasia of these
tissues. This contrasts with the category
of homeobox genes that are normally
expressed in differentiated adult tissues,
but then downregulated in cancer, exam-
ples of which include Nkx3.1 in the
prostate and Cdx2 in the colon.
Finally, the functions of homeobox
genes appear to be exquisitely sensitive
to gene dosage, which is well illustrated
in the study by Gidekel et al. One possi-
bility is that the sensitivity to dosage
reflects the significance of protein-pro-
tein interactions for mediating homeo-
protein functions; in other words, a 2-fold
difference in levels of a homeoprotein
could translate into profound effects on
gene expression simply by perturbing
the balance of protein interactions.
Alternatively, slight variations in homeo-
box gene expression may influence
the expression or functions of other
homeobox genes that may also be
dosage dependent. For example, the
newly discovered homeobox gene,
Nanog, plays a role in maintaining the
pluripotency of embryonic stem cells and
germ cells and, like Oct-4, its functions
are sensitive to variations in dosage
(Chambers et al., 2003; Mitsui et al.,
2003). It would be of interest to see if
variations in Oct-4 expression levels
affect the expression and/or function of
Nanog, either in normal germ cells or in
germ cell tumors.
In the past, the functional signifi-
cance of deregulated homeobox gene
expression in solid tumors has been sus-
pect, in part because of their relatively
subtle effects and because they display
relatively modest differences in expres-
sion levels in cancerous versus non-
cancerous cells. The study by Gidekel et
al. lends new credence to the idea that
deregulation of homeobox genes can
indeed be important in the oncogenic
process, perhaps by affecting the differ-
entiation status of the tissues in which
they are expressed. Furthermore, their
tissue specificity, association with early
stages of carcinogenesis, and sensitivity
to dosage make homeobox genes excel-
lent candidates for prognostic indicators,
as well as targets for early intervention.
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